Literature DB >> 20019700

The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA.

S-M Huang1, L Zhang, K M Giacomini.   

Abstract

The US Food and Drug Administration-led Critical Path Initiative, launched in 2004, has resulted in an array of activities focused on the sciences that support the development of human medical products.(1) These activities include the development of new scientific tools, such as in vitro testing, qualified biomarkers of drug safety, and innovative new methods in study design and data analysis.(2) As a result of the Critical Path Initiative and enormous advances in the field of membrane transporters, the International Transporter Consortium was formed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20019700     DOI: 10.1038/clpt.2009.236

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-01-27       Impact factor: 4.481

2.  An overview of transporter information in package inserts of recently approved new molecular entities.

Authors:  Sheetal Agarwal; Leslie Chinn; Lei Zhang
Journal:  Pharm Res       Date:  2012-11-28       Impact factor: 4.200

Review 3.  Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.

Authors:  Aniv Mann; Inessa Semenenko; Michal Meir; Sara Eyal
Journal:  AAPS J       Date:  2015-03-31       Impact factor: 4.009

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.

Authors:  J König; O Zolk; K Singer; C Hoffmann; M F Fromm
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades.

Authors:  Lei Zhang; Qi Liu; Shiew-Mei Huang; Robert Lionberger
Journal:  Drug Metab Dispos       Date:  2022-06-29       Impact factor: 3.579

Review 7.  An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics.

Authors:  Ahizechukwu C Eke
Journal:  J Basic Clin Physiol Pharmacol       Date:  2021-12-08

Review 8.  Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?

Authors:  Dan M Roden
Journal:  Can J Cardiol       Date:  2012-11-27       Impact factor: 5.223

9.  Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters.

Authors:  Lucy Martinez-Guerrero; Xiaohong Zhang; Kimberley M Zorn; Sean Ekins; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2021-07-12       Impact factor: 4.402

10.  A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine.

Authors:  M Jamei; F Bajot; S Neuhoff; Z Barter; J Yang; A Rostami-Hodjegan; K Rowland-Yeo
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.